Guardant Health Inc. is proud to announce that the Guardant360 CDx test has received the CE-mark for comprehensive tumor mutation profiling across all solid cancers. This is an important step to make the test more widely accessible to patients around the world. https://lnkd.in/gAHwPwP

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at [email protected] or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.